Clinical trial

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

NCT05108740

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record everolimus Normalized identity: everolimusView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

Design: EXPANDED_ACCESS · Status: NO LONGER AVAILABLE · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNO_LONGER_AVAILABLE

Study typeEXPANDED_ACCESS

Start dateUnknown

PhaseN/A

Conditions

Advanced Hormone Receptor Positive (HR+) Breast Cancerunresolved

Interventions

everolimusDRUG · verified · RxNorm: everolimus

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05108740 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.